University of California San Francisco

R. Kate Kelley, MD

R. Kate (Katie) Kelley - 144
R. Kate Kelley, MD

Health Sciences Professor of Clinical Medicine,
Division of Hematology Oncology
Department of Medicine

Address

550 16th Street, #6602
San Francisco, CA 94158
United States

Biography

Dr. Robin Kate Kelley is a gastrointestinal oncologist who specializes in cancers arising from the liver, including hepatocellular carcinoma, bile duct cancer (cholangiocarcinoma), and gallbladder carcinoma. Her research interests include developing clinical trials of new treatments and combination therapies for these cancers, including immunotherapy approaches as well as translational research to identify molecular and genetic biomarkers of response. Dr. Kelley graduated from the David Geffen School of Medicine at UCLA and completed a residency at UCLA, where she was chief resident in internal medicine. She then completed a fellowship in hematology and oncology at UCSF.

Dr. Kelley received an American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium Merit Award in 2009, an ASCO Young Investigator Award in 2010, and the National Cancer Institute Cancer Clinical Investigator Team Leadership Award in 2014. She has authored numerous publications about treatments for advanced liver and bile duct cancers. She is involved in many organizations dedicated to improving the outcomes for patients with primary liver cancers, including National Comprehensive Cancer Network (NCCN) guideline panel for Liver Cancers, the National Cancer Institute Hepatobiliary Cancer Task Force, the Cholangiocarcinoma Foundation Scientific and Medical Advisory Board, and the International Liver Cancer Association Education Committee.

Education

Institution Degree Dept or School End Date
University of California San Francisco Fellowship Hematology/Oncology 10/2009
University of California Los Angeles Chief Residency Internal Medicine 06/2006
University of California Los Angeles Residency Internal Medicine 05/2005
University of California Los Angeles M.D. School of Medicine 05/2002
Harvard College A.B. Biochemical Sciences 05/1997

Board Certifications

American Board of Internal Medicine
American Board of Internal Medicine: Medical Oncology - Subspecialty

Clinical Expertise

Colon Cancer
Hepatocellular Carcinoma (Liver Cancer)
Liver Metastases
Pancreatic Cancer
Rectal Cancer
Stomach Cancer

Program Affiliations

UCSF Helen Diller Family Comprehensive Cancer Center

Research Interests

Anal Cancer
Colorectal Cancer
 Hepatocellular Carcinoma (Liver Cancer)
Liver Metastases
Rectal Cancer
Molecular Markers in Solid Tumors

Publications

MOST RECENT PUBLICATIONS FROM A TOTAL OF 10
  1. Plain language summary of five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (liver cancer).
    Rimassa L, Chan SL, Sangro B, Lau G, Kudo M, Reig M, Breder V, Ryu MH, Ostapenko Y, Sukeepaisarnjaroen W, Varela M, Tougeron D, Crysler OV, Bouattour M, Dao TV, Tam VC, Faccio A, Furuse J, Jeng LB, Kang YK, Kelley RK, Kurland JF, Balaji K, Abou-Alfa GK| | PubMed
  2. Hallmarks of liver cancer: Therapeutic implications.
    Llovet JM, Pinyol R, Affo S, Yarchoan M, Gores GJ, Kelley RK, Lowe SW, Sia D, Villanueva A| | PubMed
  3. Erratum to 'BCLC strategy for prognosis prediction and treatment recommendations: The 2026 update' [J Hepatol (2026) 631-654].
    Reig M, Sanduzzi-Zamparelli M, Forner A, Rimola J, Ferrer-Fàbrega J, Burrel M, Garcia-Criado Á, Díaz A, Llarch N, Iserte G, Mollà M, Kelley RK, Galle PR, Mazzaferro V, Salem R, Sangro B, Singal A, Vogel A, Yanagihara TK, Ayuso C, Torres F, Bruix J| | PubMed
  4. Alanine catabolism as a targetable vulnerability for MYC-driven liver cancer.
    Montoya T, Lee JV, Qiu L, Krall A, Matulionis N, Seo Y, Finck BN, Kelley RK, Christofk H, Goga A| | PubMed
  5. Phase II trial with nivolumab and sorafenib in HCC identified enrichment of immunosuppressive monocytes in patients with Child-Pugh B liver dysfunction.
    Keenan BP, Fan Z, Le BK, Harris Q, Chen J, Clark M, Lea A, Zhang L, Cheung A, Lara F, Gordan JD, Bracci P, Behr SC, Fong L, Venook AP, Kim EJ, Kelley RK| | PubMed
  6. MAPK Pathway Mutations Emerge in Mutant IDH1 Inhibitor-Resistant Cholangiocarcinoma and Attenuate the IFN Response.
    Wan J, Saatcioglu HD, Ellis H, Aguado-Fraile E, Xu Q, Kondo H, Manguso RT, Gritti I, Norden BL, Noble C, Corcoran RB, Lubner SJ, Javle M, Abou-Alfa GK, Cleary JM, Kelley RK, Borad MJ, Macarulla T, Oh DY, Daigle S, Gliser C, Pandya S, Choe S, Tron AE, Bardeesy N| | PubMed
  7. Impact of Hepatitis B Virus Infection on the Efficacy and Safety of Pembrolizumab plus Chemotherapy for Advanced Biliary Tract Cancer in the KEYNOTE-966 Study.
    Chan SL, Yau T, Kelley RK, Finn RS, Yoo C, Furuse J, Ren Z, Klümpen HJ, Ozaka M, Pelzer U, Arslan C, Park JO, Edeline J, Valle JW, Ueno M, Vogel A, Starkopf L, Malhotra U, Siegel AB, Qin S| | PubMed
  8. T-Cell Receptor and Immune Gene Expression Pharmacodynamics for Durvalumab Alone and with Tremelimumab or Bevacizumab in Unresectable Hepatocellular Carcinoma.
    Kelley RK, Lee Y, Conway J, Kurland JF, McCoon P| | PubMed
  9. Uncovering the genetic landscape of cholangiocarcinoma and its subtypes via GWAS and integrative analyses.
    Han Y, Byun J, VanLith CJ, Cooley MA, Shaw VR, Hatia RI, Ahmed FY, Giama NH, Ali HM, Campbell NA, Hassan M, Andersen JB, Ankoma-Sey V, Banales JM, Bujanda L, Bathe OF, Bekaii-Saab TS, Borad MJ, Björkström NK, Chan CHF, Cleary SP, Cornillet M, Folseraas T, Galle PR, Genkinger JM, MacInnis RJ, Gores GJ, Goyal L, Houlston RS, Ilyas SI, Javle M, Johansen JS, Christensen TD, Kamath AS, Kelley RK, Khan SA, Kim RD, Kwee SA, Lamarca A, Lammert F, LaRusso NF, Lindsey S, Macias RIR, Malhi H, Patel TC, Permuth JB, Reeves HL, Rossi S, Sanchez W, Smoot RL, Swerdlow AJ, Tran Cao HS, Valle JW, Weinmann A, Weinmann-Menke J, Wong LL, Zhang X, Zimmer V, Zhu AX, Lazaridis KN, Juran BD, Jalal P, Knox JJ, Hutchinson A, Hicks B, Koshiol JE, Chanock SJ, Hassan MM, Amos CI, McGlynn KA, Roberts LR| | PubMed
  10. Broadening the gates: Analysis of potentially modifiable study entry criteria in pancreatic and biliary tract cancer trials.
    Saj F, Namayanja FK, Xiao L, Borad MJ, Kelley RK, Goyal L, Azad NS, Bachini M, Lindsey S, Pant S, Valle JW, Fashoyin-Aje LA, Javle M| | PubMed